Effectiveness of trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: 2012/13 end of season results

被引:40
作者
Andrews, N. [1 ]
McMenamin, J. [2 ]
Durnall, H. [3 ]
Ellis, J. [4 ]
Lackenby, A. [4 ]
Robertson, C. [2 ,5 ,6 ]
von Wissmann, B. [2 ]
Cottrell, S. [7 ]
Smyth, B. [8 ]
Moore, C. [7 ]
Gunson, R. [9 ]
Zambon, M. [4 ]
Fleming, D. [3 ]
Pebody, R. [1 ]
机构
[1] Publ Hlth England Hlth Protect Directorate, London, England
[2] Hlth Protect Scotland, Glasgow, Lanark, Scotland
[3] Royal Coll Gen Practitioners, Res & Surveillance Ctr, Birmingham, W Midlands, England
[4] Publ Hlth England Operat Directorate, Microbiol Serv, London, England
[5] Univ Strathclyde, Glasgow, Lanark, Scotland
[6] Int Prevent Res Inst, Lyon, France
[7] Publ Hlth Wales, Cardiff, S Glam, Wales
[8] Publ Hlth Agcy Northern Ireland, Belfast, Antrim, North Ireland
[9] West Scotland Specialist Virol Ctr, Glasgow, Lanark, Scotland
来源
EUROSURVEILLANCE | 2014年 / 19卷 / 27期
关键词
DESIGNS; AGE;
D O I
10.2807/1560-7917.ES2014.19.27.20851
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The effectiveness of the 2012/13 trivalent seasonal influenza vaccine (TIV) was assessed using a testnegative case-control study of patients consulting primary care with influenza-like illness in the United Kingdom. Strain characterisation was undertaken on selected isolates. Vaccine effectiveness (VE) against confirmed influenza A(H3N2), A(H1N1) and B virus infection, adjusted for age, sex, surveillance scheme (i.e. setting) and month of sample collection was 26% (95% confidence interval (CI): -4 to 48), 73% (95% CI: 37 to 89) and 51% (95% CI: 34 to 63) respectively. There was an indication, although not significant, that VE declined by time since vaccination for influenza A(H3N2) (VE 50% within three months, 2% after three months, p=0.25). For influenza A(H3N2) this is the second season of low VE, contributing to the World Health Organization (WHO) recommendation that the 2013/14 influenza vaccine strain composition be changed to an A(H3N2) virus antigenically like cell-propagated prototype 2012/13 vaccine strain (A/Victoria/361/2011). The lower VE seen for type B is consistent with antigenic drift away from the 2012/13 vaccine strain. The majority of influenza B viruses analysed belong to the genetic clade 2 and were antigenically distinguishable from the 2012/13 vaccine virus B/Wisconsin/1/2010 clade 3. These findings supported the change to the WHO recommended influenza B vaccine component for 2013/14.
引用
收藏
页码:5 / 13
页数:9
相关论文
共 21 条
[1]  
[Anonymous], EURO SURVEILL
[2]  
[Anonymous], EURO SURVEILL
[3]  
[Anonymous], EURO SURVEILL
[4]  
[Anonymous], SURV INFL OTH RESP V
[5]  
De Serres G, 2013, EURO SURVEILL, V18, P20585
[6]  
Ellis J, 2009, EUROSURVEILLANCE, V14
[7]   Influenza vaccination status is not associated with influenza testing among children: Implications for observational studies of vaccine effectiveness [J].
Ferdinands, Jill M. ;
Belongia, Edward A. ;
Nwasike, Chinyelu ;
Shay, David K. .
VACCINE, 2011, 29 (10) :1935-1940
[8]   Estimating influenza vaccine effectiveness using routinely collected laboratory data [J].
Fleming, D. M. ;
Andrews, N. J. ;
Ellis, J. S. ;
Bermingham, A. ;
Sebastianpillai, P. ;
Elliot, A. J. ;
Miller, E. ;
Zambon, M. .
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2010, 64 (12) :1062-1067
[9]   Development of a multiplex real-time RT-PCR that allows universal detection of influenza A viruses and simultaneous typing of influenza A/H1N1/2009 virus [J].
Gunson, Rory ;
Maclean, Alasdair ;
Davies, Eleri ;
Bennett, Susan ;
Miller, Rhona ;
Carman, W. F. .
JOURNAL OF VIROLOGICAL METHODS, 2010, 163 (02) :258-261
[10]  
HAKIN B, 2013, CHILDRENS FLU IMMUNI